Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSmithers, B.M.en
dc.contributor.authorFahey, P.P.en
dc.contributor.authorCorish, T.en
dc.contributor.authorGotley, D.C.en
dc.contributor.authorFalk, G.L.en
dc.contributor.authorSmith, G.S.en
dc.contributor.authorKiroff, G.K.en
dc.contributor.authorClouston, A.D.en
dc.contributor.authorWatson, D.I.en
dc.contributor.authorWhiteman, D.C.en
dc.identifier.citationMedical Journal of Australia, 2010; 193(10):572-577en
dc.description.abstractOBJECTIVE: To document presenting symptoms, investigations and management for Australian patients with oesophageal adenocarcinoma (OAC), gastro-oesophageal junction adenocarcinoma (GOJAC) and oesophageal squamous cell carcinoma (OSCC). DESIGN, SETTING AND PARTICIPANTS: Cross-sectional study of a population-based sample of 1100 Australian patients aged 18-79 years with histologically confirmed oesophageal cancer diagnosed in 2002-2005, using data from cancer registries and treatment centres, supplemented with clinical information collected through medical record review in 2006-2007 and mortality information collected in 2008. MAIN OUTCOME MEASURES: Prevalence of primary symptoms, and staging investigations and treatment modalities used. RESULTS: The primary presenting symptom was dysphagia, which was self-reported by 41%, 39% and 48% of patients with OAC, GOJAC and OSCC, respectively. Less common symptoms were reflux, chest pain, bleeding and weight loss. All patients underwent endoscopy, most had a staging computed tomography scan (OAC 93%, GOJAC 95% and OSCC 93%), and about half had positron emission tomography scans (OAC 51%, GOJAC 44% and OSCC 42%). Pretreatment tumour stage was reported in 25% of records, and could be derived from results of investigations in a further 23%, but the remaining half lacked sufficient information to ascribe a pretreatment stage. Curative treatments were attempted for 60% of OAC, 88% of GOJAC and 65% of OSCC patients. Surgery was performed on 52% of OAC, 83% of GOJAC and 41% of OSCC patients. About two-thirds of surgical patients received additional therapies. CONCLUSIONS: With anticipated increases in oesophageal cancer incidence, the resources required to diagnose and manage patients with oesphageal cancer are also likely to rise. Our data provide a baseline from which to plan for the future care of patients with cancers of the oesophagus.en
dc.description.statementofresponsibilityBernard M Smithers, Paul P Fahey, Tracie Corish, David C Gotley, Gregory L Falk, Garett S Smith, George K Kiroff, Andrew D Clouston, David I Watson and David C Whitemanen
dc.publisherAustralasian Medical Publishing Companyen
dc.rights© Australasian Medical Publishing Companyen
dc.subjectEsophagogastric Junction; Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Incidence; Prevalence; Neoplasm Staging; Sex Distribution; Aged; Cross-Sectional Studies; Deglutition Disordersen
dc.titleSymptoms, investigations and management of patients with cancer of the oesophagus and gastro-oesophageal junction in Australiaen
dc.typeJournal articleen
dc.identifier.orcidKiroff, G.K. [0000-0003-0523-5311]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.